Payment overview · 2025
General Payments
$34,597.15
105 reported records · 21 companies
Healthcare provider profile · identity verified
Isha Gupta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · MIDDLETOWN, NY · NPI 1922345008
Verified facts
What the public records show
CMS Open Payments records show Isha Gupta, M.D. received $34,597.15 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 95.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Acthar, Eliquis, Farxiga, Jardiance, Kerendia, Ozempic, Rayaldee, Trelegy Ellipta, Veltassa.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Mallinckrodt Hospital Products Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ACTHAR as an associated drug or biological on 35914 records involving 11592 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Acthar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rayaldee by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33,045.26 | 95.5% | 30 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $287.72 | 0.8% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.82 | 0.6% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $156.06 | 0.5% | 10 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $96.67 | 0.3% | 7 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $89.90 | 0.3% | 5 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $89.04 | 0.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.51 | 0.2% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $76.77 | 0.2% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $60.85 | 0.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.62 | 0.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $48.08 | 0.1% | 1 | 2025 |
| NxStage Medical, Inc. | Unresolved — no canonical attribution shown | $46.45 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.34 | 0.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $40.73 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.76 | 0.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.94 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.77 | 0.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $27.10 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.21 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.55 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,880.63 | 9 |
| Travel and Lodging | $6,143.65 | 9 |
| Food and Beverage | $2,221.63 | 76 |
| Education | $351.24 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32,964.49 | 27 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $287.72 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $117.30 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $97.41 | 4 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $89.90 | 5 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $89.04 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $83.19 | 5 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $76.77 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $67.34 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $60.85 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $56.49 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.62 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.45 | 2 | 2025 |
Source payment records
|
|||||
| FABRAZYME Normalized: fabrazyme |
Biological | GENZYME CORPORATION | $48.08 | 1 | 2025 |
Source payment records
|
|||||
| NXSTAGE SYSTEM ONE Normalized: nxstage system one |
Device | NxStage Medical, Inc. | $46.45 | 1 | 2025 |
Source payment records
|
|||||
| PUREFLOW SL Normalized: pureflow sl |
Device | NxStage Medical, Inc. | $46.45 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $44.03 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.67 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $40.73 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ACTHAR acthar |
2025 | Acthar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 410 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 239 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
410 | 153 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
24 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
239 | 78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 25 |
| Mallinckrodt Hospital Products Inc. Exact reporting entity; no affiliate inference |
2025 | ACTHAR open payments reported associated product |
CMS Open Payments — General Payments 35914 supporting records · 11592 recipient NPIs · example record 1211945432 |
Acthar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | 13 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
39 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Farxiga | Dapagliflozin Propanediol | 410 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 106 |
| Kerendia | Finerenone | 239 | 78 |
| Losartan Potassium | Losartan Potassium | 216 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 177 | 72 |
| Furosemide | Furosemide | 140 | 60 |
| Lisinopril | Lisinopril | 139 | 56 |
| Ozempic | Semaglutide | 93 | 30 |
| Omeprazole | Omeprazole | 92 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 82 | 31 |
| Metformin Hcl | Metformin Hcl | 81 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 38 |
| Calcitriol | Calcitriol | 71 | 32 |
| Labetalol Hcl | Labetalol Hcl | 65 | 26 |
| Tramadol Hcl | Tramadol Hcl | 62 | 25 |
| Gabapentin | Gabapentin | 61 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 19 |
| Potassium Chloride | Potassium Chloride | 48 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 25 |
| Simvastatin | Simvastatin | 44 | 11 |
| Allopurinol | Allopurinol | 42 | 19 |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | 12 |
| Bumetanide | Bumetanide | 40 | 22 |
| Carvedilol | Carvedilol | 40 | 16 |
| Rayaldee | Calcifediol | 40 | 13 |
| Veltassa | Patiromer Calcium Sorbitex | 39 | 24 |
| Jardiance | Empagliflozin | 37 | 25 |
| Azithromycin | Azithromycin | 36 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 21 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 30 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 12 |
| Lokelma | Sodium Zirconium Cyclosilicate | 24 | 11 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Famotidine | Famotidine | 20 | 12 |
| Glipizide | Glipizide | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Eliquis | Apixaban | 15 | suppressed |
| Metolazone | Metolazone | 15 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Acthar | Corticotropin | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,597.15 · 105 records | Novo Nordisk Inc | ACTHAR, AIRSUPRA, AREXVY, BEXSERO, BREZTRI, CRYSVITA, Cologuard Collection Kit, ELIQUIS, FABRAZYME, FARXIGA, FUROSCIX, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LEQVIO, NURTEC ODT, NXSTAGE SYSTEM ONE, Ozempic, PUREFLOW SL, RAYALDEE, REXULTI, SHINGRIX, TARPEYO, TAVNEOS, TRELEGY ELLIPTA, VOYXACT, Veltassa | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Acthar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error